While Kaleido Biosciences, Inc. (NASDAQ:KLDO) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 28% in the last quarter. Taking a longer term view we see the stock is up over one year. However, its return of 12% does fall short of the market return of, 38%.

Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.

See our latest analysis for Kaleido Biosciences

Kaleido Biosciences wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Kaleido Biosciences grew its revenue by 393% last year. That's a head and shoulders above most loss-making companies. Let's face it the 12% share price gain in that time is underwhelming compared to the growth. When revenue spikes but the share price doesn't we can't help wondering if the market is missing something. It's possible that the market is worried about the losses, or simply that the growth was already priced in. Or, this could be worth adding to your watchlist.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. This free report showing analyst forecasts should help you form a view on Kaleido Biosciences

A Different Perspective

We're happy to report that Kaleido Biosciences are up 12% over the year. The bad news is that's no better than the average market return, which was roughly 38%. The last three months haven't been great for shareholder returns, since the share price has trailed the market by 29% in the last three months. It might be that investors are more concerned about the business lately due to some fundamental change (or else the share price simply got ahead of itself, previously). It's always interesting to track share price performance over the longer term. But to understand Kaleido Biosciences better, we need to consider many other factors. Case in point: We've spotted 5 warning signs for Kaleido Biosciences you should be aware of, and 1 of them doesn't sit too well with us.